Incyte Corp (INCY) 75.94 $INCY
Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:20AM CST
Incyte Corporation (INCY) reported a fourth-quarter 2014 loss of 22 cents per share, wider than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 15 cents per share.
ALNY: 95.54 (+1.67), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), NVS: 102.20 (-0.17)
Incyte's (INCY) CEO Hervé Hoppenot on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 1:35PM CST
INCY: 75.94 (+0.28)
Incyte ups revenues 44% in FY14
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:39AM CST
INCY: 75.94 (+0.28)
Should You Sell Incyte (INCY) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:51AM CST
Incyte is poised to beat at earnings season as it is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
INCY: 75.94 (+0.28)
Incyte (INCY) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:25AM CST
INCY: 75.94 (+0.28)
Incyte misses by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:06AM CST
INCY: 75.94 (+0.28)
Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs
Business Wire - Thu Feb 12, 6:00AM CST
--$358 million of 2014 full-year net product revenues from Jakafi, representing 52 percent growth over last year
INCY: 75.94 (+0.28)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 104.71 (+0.67), VRTX: 113.66 (+4.03), ARWR: 6.77 (+0.21), INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
Look for Shares of Incyte to Potentially Rebound after Yesterday's 3.87% Sell Off
Comtex SmarTrend(R) - Wed Feb 04, 4:38PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $72.62 to a high of $75.39. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $73.25 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 75.94 (+0.28)
Watch for Incyte to Potentially Rebound After Falling 3.87% Yesterday
Comtex SmarTrend(R) - Wed Feb 04, 4:37PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $72.62 to a high of $75.39. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $73.25 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 75.94 (+0.28)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
at The Street - Fri Jan 30, 7:39AM CST
The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.
INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02)
Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:35PM CST
Incyte Corporation (INCY) announced the publication of data from a pivotal phase III study (RESPONSE) on Jakafi conducted in patients with uncontrolled polycythemia vera in the New England Journal of Medicine.
INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Earnings Peek: Don't Expect Incyte To Be Profitable In 2014
Clinically Sound Investor - at Seeking Alpha - Thu Jan 29, 1:20PM CST
INCY: 75.94 (+0.28)
Unilife: Ready For Phase 2 Of A Huge Move
RightEdge Analytics - Seeking Alpha - Thu Jan 29, 10:44AM CST
Update: This article is to update on the recent announcements and runup in share price since the first article that we published on Unilife (NASDAQ: UNIS ) on September 19, 2014 . Since this article UNIS has increased in value by about 70%. This is...
UNIS: 4.32 (+0.06), JPM: 59.67 (+0.10), INCY: 75.94 (+0.28), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82)
Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:20AM CST
Incyte Corporation (INCY) reported a fourth-quarter 2014 loss of 22 cents per share, wider than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 15 cents per share.
ALNY: 95.54 (+1.67), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), NVS: 102.20 (-0.17)
Incyte's (INCY) CEO Hervé Hoppenot on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 1:35PM CST
INCY: 75.94 (+0.28)
Incyte ups revenues 44% in FY14
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:39AM CST
INCY: 75.94 (+0.28)
Should You Sell Incyte (INCY) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:51AM CST
Incyte is poised to beat at earnings season as it is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
INCY: 75.94 (+0.28)
Incyte (INCY) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:25AM CST
INCY: 75.94 (+0.28)
Incyte misses by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:06AM CST
INCY: 75.94 (+0.28)
Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs
Business Wire - Thu Feb 12, 6:00AM CST
--$358 million of 2014 full-year net product revenues from Jakafi, representing 52 percent growth over last year
INCY: 75.94 (+0.28)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 104.71 (+0.67), VRTX: 113.66 (+4.03), ARWR: 6.77 (+0.21), INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
Look for Shares of Incyte to Potentially Rebound after Yesterday's 3.87% Sell Off
Comtex SmarTrend(R) - Wed Feb 04, 4:38PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $72.62 to a high of $75.39. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $73.25 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 75.94 (+0.28)
Watch for Incyte to Potentially Rebound After Falling 3.87% Yesterday
Comtex SmarTrend(R) - Wed Feb 04, 4:37PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $72.62 to a high of $75.39. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $73.25 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 75.94 (+0.28)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
at The Street - Fri Jan 30, 7:39AM CST
The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.
INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02)
Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:35PM CST
Incyte Corporation (INCY) announced the publication of data from a pivotal phase III study (RESPONSE) on Jakafi conducted in patients with uncontrolled polycythemia vera in the New England Journal of Medicine.
INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Earnings Peek: Don't Expect Incyte To Be Profitable In 2014
Clinically Sound Investor - at Seeking Alpha - Thu Jan 29, 1:20PM CST
INCY: 75.94 (+0.28)
Unilife: Ready For Phase 2 Of A Huge Move
RightEdge Analytics - Seeking Alpha - Thu Jan 29, 10:44AM CST
Update: This article is to update on the recent announcements and runup in share price since the first article that we published on Unilife (NASDAQ: UNIS ) on September 19, 2014 . Since this article UNIS has increased in value by about 70%. This is...
UNIS: 4.32 (+0.06), JPM: 59.67 (+0.10), INCY: 75.94 (+0.28), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82)
